MarketBeat
17 Nov 2026, 06:13 UTC · 6h ago
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
Impact · against what's priced in
Solid Biosciences (SLDB) sees a positive catalyst in the potential acceleration of its BLA filing to mid-2027 and the absence of severe safety signals that have plagued its competitors. The lack of liver injury or myocarditis in 53 patients significantly derisks the lead program relative to the current sector sentiment.
- SRPT−0.90
No priced-in read yet





